Trial Profile
An open-label, single-sequence pharmacokinetic study in healthy subjects to assess the potential of AEB071 to inhibit and induce CYP1A2 using caffeine as a probe substrate.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Sotrastaurin (Primary) ; Caffeine
- Indications Liver transplant rejection; Psoriasis; Renal transplant rejection
- Focus Pharmacokinetics
- Sponsors Novartis
- 07 Jan 2013 Status changed from recruiting to active, no longer recruiting, according to Clinical Trials Registry - India
- 10 Feb 2010 New trial record